BCL11A and thalassemia: Our findings are in line with one of the latest CRISPR/Cas9-based studies showing that disruption of either the LRF/ZBTB7A or BCL11A binding site comparably reactivates γ-globin expression, suggesting that both are viable therapeutic targets for β0-thalassemia [24].